BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8077061)

  • 1. Interleukin-4 receptors expressed on tumor cells may serve as a target for anticancer therapy using chimeric Pseudomonas exotoxin.
    Debinski W; Puri RK; Pastan I
    Int J Cancer; 1994 Sep; 58(5):744-8. PubMed ID: 8077061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A wide range of human cancers express interleukin 4 (IL4) receptors that can be targeted with chimeric toxin composed of IL4 and Pseudomonas exotoxin.
    Debinski W; Puri RK; Kreitman RJ; Pastan I
    J Biol Chem; 1993 Jul; 268(19):14065-70. PubMed ID: 8314773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin.
    Puri RK; Debinski W; Obiri N; Kreitman R; Pastan I
    Cell Immunol; 1994 Apr; 154(1):369-79. PubMed ID: 8131209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4.
    Debinski W; Obiri NI; Pastan I; Puri RK
    J Biol Chem; 1995 Jul; 270(28):16775-80. PubMed ID: 7622490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A chimeric protein comprised of IL-4 and Pseudomonas exotoxin is cytotoxic for activated human lymphocytes.
    Puri RK; Mehrotra PT; Leland P; Kreitman RJ; Siegel JP; Pastan I
    J Immunol; 1994 Apr; 152(7):3693-700. PubMed ID: 8144944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells.
    Debinski W; Miner R; Leland P; Obiri NI; Puri RK
    J Biol Chem; 1996 Sep; 271(37):22428-33. PubMed ID: 8798406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein.
    Puri RK; Leland P; Kreitman RJ; Pastan I
    Int J Cancer; 1994 Aug; 58(4):574-81. PubMed ID: 8056454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.
    Kreitman RJ; Puri RK; Pastan I
    Cancer Res; 1995 Aug; 55(15):3357-63. PubMed ID: 7614471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity.
    Puri RK; Leland P; Obiri NI; Husain SR; Mule J; Pastan I; Kreitman RJ
    Cell Immunol; 1996 Jul; 171(1):80-6. PubMed ID: 8660841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo.
    Leland P; Taguchi J; Husain SR; Kreitman RJ; Pastan I; Puri RK
    Mol Med; 2000 Mar; 6(3):165-78. PubMed ID: 10965493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
    Kawakami K; Kawakami M; Joshi BH; Puri RK
    Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
    Puri RK; Leland P; Obiri NI; Husain SR; Kreitman RJ; Haas GP; Pastan I; Debinski W
    Blood; 1996 May; 87(10):4333-9. PubMed ID: 8639793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4.
    Kornmann M; Kleeff J; Debinski W; Korc M
    Anticancer Res; 1999; 19(1A):125-31. PubMed ID: 10226533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
    Kreitman RJ; Chang CN; Hudson DV; Queen C; Bailon P; Pastan I
    Int J Cancer; 1994 Jun; 57(6):856-64. PubMed ID: 8206679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo activities of acidic fibroblast growth factor-Pseudomonas exotoxin fusion proteins.
    Siegall CB; Gawlak SL; Chace DF; Merwin JR; Pastan I
    Bioconjug Chem; 1994; 5(1):77-83. PubMed ID: 7515280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.
    Husain SR; Joshi BH; Puri RK
    Int J Cancer; 2001 Apr; 92(2):168-75. PubMed ID: 11291041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basic fibroblast growth factor-Pseudomonas exotoxin chimeric proteins; comparison with acidic fibroblast growth factor-Pseudomonas exotoxin.
    Gawlak SL; Pastan I; Siegall CB
    Bioconjug Chem; 1993; 4(6):483-9. PubMed ID: 7508267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.
    Joshi BH; Kawakami K; Leland P; Puri RK
    Clin Cancer Res; 2002 Jun; 8(6):1948-56. PubMed ID: 12060640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy.
    Husain SR; Behari N; Kreitman RJ; Pastan I; Puri RK
    Cancer Res; 1998 Aug; 58(16):3649-53. PubMed ID: 9721874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
    Beseth BD; Cameron RB; Leland P; You L; Varricchio F; Kreitman RJ; Maki RA; Jablons DM; Husain SR; Puri RK
    Ann Thorac Surg; 2004 Aug; 78(2):436-43; discussion 436-43. PubMed ID: 15276492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.